Scribe sold 8,580,000 shares at $15.00 with a going concern warning in its prospectus. The company had $49.7 million in cash and marketable securities at March 31, 2026, against $40.5 million in outstanding indebtedness.
Scribe Therapeutics filed an S-1 on July 2, 2026 with blank share and price terms. Management and its auditor have raised substantial doubt about its ability to continue as a going concern.
Questions about Scribe Therapeutics
Has Scribe Therapeutics issued a going-concern warning?
Our latest story on this, dated Jul 27, 2026: "Scribe Therapeutics prices IPO of 8,580,000 shares at $15.00". The story links the filing or release it is based on. Read the story.
When did Scribe Therapeutics go public?
Our latest story on this, dated Jul 27, 2026: "Scribe Therapeutics prices IPO of 8,580,000 shares at $15.00". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Scribe Therapeutics?
Scribe Therapeutics Inc. trades under the ticker SCTX on NASDAQ.
Where is Scribe Therapeutics listed?
Scribe Therapeutics Inc. is listed on NASDAQ.
What is the SEC CIK of Scribe Therapeutics?
The SEC Central Index Key (CIK) for Scribe Therapeutics Inc. is 1853921. Its filings are on SEC EDGAR.
How many shares does Scribe Therapeutics have outstanding?
18,931,680 shares as of 2026-08-31, per the cover page of its 10-Q filed 2026-09-02.
Which country or territory is Scribe Therapeutics listed under?
Our directory records Scribe Therapeutics Inc. under United States.
What does Scribe Therapeutics do?
Our directory classifies Scribe Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Scribe Therapeutics?
The ISIN recorded for Scribe Therapeutics Inc. is US8110331092.
Does aibio.space cover Scribe Therapeutics?
aibio.space lists Scribe Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Scribe Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Scribe Therapeutics (SCTX) stock news?
Our latest story on Scribe Therapeutics, dated Jul 27, 2026: "Scribe Therapeutics prices IPO of 8,580,000 shares at $15.00". Scribe sold 8,580,000 shares at $15.00 with a going concern warning in its prospectus. The company had $49.7 million in cash and marketable securities at March 31, 2026, against $40.5 million in outstanding indebtedness. Source.
What is Scribe Therapeutics's latest stock offering or financing news?
Our latest financing story, dated Jul 27, 2026: "Scribe Therapeutics prices IPO of 8,580,000 shares at $15.00". Scribe sold 8,580,000 shares at $15.00 with a going concern warning in its prospectus. The company had $49.7 million in cash and marketable securities at March 31, 2026, against $40.5 million in outstanding indebtedness. Source.
Who were the underwriters or placement agents on Scribe Therapeutics's offering?
From our story: Leerink Partners LLC, Goldman Sachs & Co. LLC, Guggenheim Securities, LLC and Wells Fargo Securities, LLC are the representatives of the underwriters. Source.
How long will Scribe Therapeutics's cash last?
From our story of Jul 27, 2026: Scribe sold 8,580,000 shares at $15.00 with a going concern warning in its prospectus. Source.
Investor discussion: Scribe Therapeutics
Members talk about Scribe Therapeutics (SCTX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Scribe Therapeutics, newest first. Each line links the filing it comes from.
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:SCTX on TradingView.
SEC filings and registration
SEC name
Scribe Therapeutics, Inc.
CIK
1853921
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
SCTX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
1150 MARINA VILLAGE PKWY, ALAMEDA, CA, 94501
Phone
510-454-0213
Shares outstanding
18,931,680 as of 2026-08-31 (10-Q filed 2026-09-02)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Scribe Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SCTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio